期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌的抗体治疗的研究进展 被引量：1

Antibody treatment of lung cancer:recent progress
在线阅读 下载PDF
导出
摘要 肺癌的传统疗法效果不够理想,用抗体治疗肺癌是一较为有效的方法。目前主要有5类抗体用于治疗肺癌:(1)西妥昔单抗(Cetuximab)、ABX-EGF(Panitumumab)、Matuzumab(EMD72000)和曲妥珠单抗(Herceptin)等,这类抗体通过结合肿瘤细胞表面分子抑制细胞生长,具有较好的疗效,是目前研究的热点;(2)贝伐单抗(Bevacizumab),通过抑制肿瘤新生血管形成,阻断肿瘤的营养来源和转移通道,达到治疗肿瘤的目的;(3)BEC2、3F6和3F6ScFv,它们作为治疗性抗独特型抗体疫苗可以激活免疫系统,诱导抗肿瘤反应,临床应用还有待进一步研究;(4)抗体偶联效应分子,如90Y-CC49、131I-chTNT和5F11-DOX可以靶向杀伤,作用更有针对性,减少正常组织受损;(5)Catumaxomab(removab)和OKT3×Antag2,作为双特异性抗体可以联接肿瘤细胞和免疫效应细胞,增强杀伤作用。抗体治疗肺癌可以弥补传统治疗的不足,抗体治疗与传统治疗联合应用可有效提高对肺癌的疗效。
作者 李冕 田野苹 孙卫民
机构地区 第二军医大学学员队 第二军医大学免疫学研究所
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2007年第3期296-300,共5页 Chinese Journal of Cancer Biotherapy
关键词 肺癌 治疗 抗体
分类号 R734 [医药卫生—肿瘤]
作者简介 李冕（1986-），男，福建莆田人，本科，主要从事生物技术方面的研究. Corresponding author. E-mail ： typimm@ hotmail. com.
  • 相关文献

参考文献23

  • 1吕峰,胡云章,姜述德.表皮生长因子受体抑制剂在肿瘤治疗方面的研究进展[J].中国肿瘤生物治疗杂志,2004,11(1):75-77. 被引量：5
  • 2Thienelt CD,Bunn PA Jr,Hanna N,et al.Multicenter phase Ⅰ/Ⅱ study of cetuximab with paclitaxel and carbophtin in untreated patients with stage Ⅳ non-small-cell lung cancer[J].J Clin Oncol,2005,23(34):8786-8793.
  • 3Robert F,Blumenschein G,Herbst RS,et al.Phase Ⅰ/Ⅱ a study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer[J].J Clin Oncol,2005,23(36):9089-9096.
  • 4Crawford J,Sandler AB,Hammond LA,et al.ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer(NSCLC)[R].J Clin Oncol,2004,22(14):7083.
  • 5Kollmannsberger C,Schittenhelm M,Honecker F,et al.A phaseⅠ study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000(matuzumab)in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer(NSCLC)[J].Ann Oncol,2006,17(6):1007-1013.
  • 6Zinner RG,Glisson BS,Fossella FV,et al.Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overex-pressing,untreated,advanced non-small cell lung cancer:report of a phase Ⅱ trial and findings regarding optimal identification of patients with Her2-overexpressing disease[J].Lung Cancer,2004,44(1):99-110.
  • 7Yoshimoto Y,Kawada M,Ikeda D,et al.Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo[J].Int Immunopharmacol,2005,5(2):281-288.
  • 8郝颖,刘晓平,徐勤,魏小勇.Fas系统与肿瘤免疫逃逸的研究进展[J].中国肿瘤生物治疗杂志,2006,13(3):224-226. 被引量：6
  • 9Livingston PO,Hood C,Krug LM,et al.Selection of GM2,fucosyl GM1,globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy[J].Cancer Immunol Immunother,2005,54(10):1018-1025.
  • 10Bremnes RM,Rafael CC.Angiogenesis in non-small cell lung cancer:the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in turnours and blood[J].Lung Cancer,2006,51(2):143-158.

二级参考文献97

  • 1Wells A. Molecules in focus EGFR receptor [ J ]. Int J Biochem Cell Biol, 1999, 31 : 637-643.
  • 2Woodbum JR. The epidermal growth factor receptor and its inhibition in cancer therapy[ J]. Phannacol Ther, 1999, 82 : 241-250.
  • 3Moscatello DK, Holgado-Madruga M, Endet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor [ J ]. J Biol Chem,1998, 273:200-206.
  • 4Mendelaohn J. Blockade of receptors for growth factors: An anticancer therapy[ J]. Clin Cancer Res, 2000, 6: 747-753.
  • 5Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model[J]. Clin Cancer Res, 1995, 1 : 1311-1318.
  • 6Bruns CJ, Harbison M T, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms[ J ]. Clin Cancer Res, 2000,ft. 1936-1948.
  • 7Huang SM, Harari P. Modulation of radiation response after epidermal gcowth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis[J]. Clin Cancer Res, 2000, 6: 2166-2174.
  • 8Baselga J, Pfister D, Cooper M R, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin[ J]. J Clin Oncol, 2000, 18: 904-914.
  • 9Yang XD, Jia XC, Corvalan JRF, et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer treatment[J]. Proc Am Soc Clin Oncol, 2000, 19: 48.
  • 10Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors[ J]. Proc Natl Acad Sci U S A, 2000, 97 : 7503-7508.

共引文献15

同被引文献29

  • 1傅相平,李安民,张志文,闫润民,易林华,刘爱军.^(131)I-肿瘤细胞核人鼠嵌合单抗脑胶质瘤瘤内放免治疗研究[J].中华实验外科杂志,2005,22(1):102-103. 被引量：12
  • 2石磊,岳媛潘,曼丽.^(131)I标记单克隆抗体C50在胃癌放射免疫导向手术中的应用[J].陕西医学杂志,2005,34(10):1199-1201. 被引量：1
  • 3许国辉,张智慧,李政文,文华长,胡大武,段天红,文永君,吴辉,杨承莲,曹蓉.^(131)I肝癌单抗片段HAb18F(ab)_2灌注治疗原发性肝癌的临床研究[J].介入放射学杂志,2005,14(6):596-598. 被引量：10
  • 4刘黎,李少林.^(131)I-2F7抗体在荷小细胞肺癌裸鼠体内分布及其对肿瘤的生长抑制作用[J].中华核医学杂志,2006,26(6):357-360. 被引量：7
  • 5Palanca-Wessels MC,Press OW.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.Cancer,2010,116(4 Suppl):1126-1133.
  • 6Goldsmith SJ.Radioimmunotherapy of lymphoma:Bexxar and Zevalin.Semin Nucl Med,2010,40(2):122-135.
  • 7Jacobs SA,Swerdlow SH,Kant J,et al.Phase Ⅱ trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Clin CancerRes,2008,14(21):7088-7094.
  • 8Schilder R,Molina A,Bartlett N,et al.Follow-up results of a phase Ⅱ study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.Cancer Biother Radiopharm,2004,19(4):478-481.
  • 9Nademance A,Forman S,Molina A,et al.A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell trans-plantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.Blood,2005,106(8):2896-2902.
  • 10Gibson AD.Updated results of a phase Ⅲ trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma.Clin Lymphoma,2002,3(2):87-89.

引证文献1

中国肿瘤生物治疗杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部